Counterpoint: Because some surrogate end point biomarkers measure the neoplastic process they will have high utility in the development of cancer chemopreventive agents against sporadic cancers

Gary J. Kelloff, Joyce A. O'Shaughnessy, Gary B. Gordon, Ernest T. Hawk, Caroline C. Sigman

Research output: Contribution to journal › Review article › peer-review

12 Scopus citations

Fingerprint

Dive into the research topics of 'Counterpoint: Because some surrogate end point biomarkers measure the neoplastic process they will have high utility in the development of cancer chemopreventive agents against sporadic cancers'. Together they form a unique fingerprint.